AstraZeneca PLC, AZN, AZN.L, ZEG.DE, AZN.ST, FDA Calendar, PDUFA Date

Company Name	AstraZeneca PLC AZN, AZN.L, ZEG.DE, AZN.ST
Drug Name	Truqap (sNDA)
Event Name	FDA panel to review Truqap in combination with abiraterone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer
Event Date	04/30/2026
Outcome Date	04/30/2026
Outcome	FDA panel recommended Truqap in combination with abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer on Apr.30, 2026
Drug Status
Rival Drugs
Market Potential
Other Approvals	Truqap, in combination with fulvestrant, received FDA approval in November 2023 for the treatment of advanced hormone receptor-positive breast cancer.
News

Return to FDA Calendar

Slide Shows